NCT05557851 - Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions

Metastatic Adenocarcinoma of the Pancreas

Interventions

COMBINATION_PRODUCT

Minnelide

Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.

Trial Locations (1)

135-710

RECRUITING

Samsung Medical Center, Soeul